The US Food and Drug Administration (FDA) has granted orphan-drug designation to biopharmaceutical company MediciNova Inc.'s MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).



